Takeda Appoints Toshio Fujimoto, MD, MBA, as General Manager of the Health Innovation Park in Shonan
2017年12月1日 - 11:00AM
ビジネスワイヤ(英語)
Takeda Pharmaceutical Company Limited [TSE: 4502] announced
today that Toshio Fujimoto, MD, MBA has been appointed General
Manager of the Health Innovation Park in Shonan. The appointment is
effective as of December 1, 2017. In this new role, Dr. Fujimoto,
who joins Takeda from Eli Lilly Japan, will provide strategic
leadership and oversight for all key Park activities, including:
development and execution of business and financial plans,
coordination of site operations and services, tenant recruitment
and management, and marketing and public relations activities. Dr.
Fujimoto will be accountable to a newly formed Management Board
comprised of Takeda executives. The Management Board will be led by
Seigo Izumo (Global Head of Regenerative Medicine Unit, Head of
Scientific Affairs, Japan), who will serve as Chair, and will
include Salvatore Alesci (Head of R&D Global Science and
Biomedical Policy) and Haruhiko Hirate (Corporate Officer,
Corporate Communications and Public Affairs Officer). The
Management Board will provide counsel and support decision-making
as Takeda continues to establish the Park’s ecosystem and maintain
efforts to build meaningful collaborations with academic
institutions, biotech and biopharmaceutical companies and other
partners.
Dr. Fujimoto brings to Shonan diverse R&D experience, strong
leadership skills and business acumen. In his most recent role as
Vice President, Medicine Development Unit at Eli Lilly Japan – a
position which he held since 2015, he oversaw the R&D
Management function in Japan. Dr. Fujimoto received his MD from
Kyoto University and his MBA from Kobe University. He began his
clinical practice as a Resident in the Department of Thoracic
Surgery at Kyoto University Hospital. After completing several
rotations at local area hospitals, he took a position in Germany as
Assistant Surgeon with the Thoracic Surgery Department at
Ruhrlandklink Hospital, and later moved to the U.S. to serve as
Clinical Fellow, General Thoracic Surgery at the Mayo Clinic.
“The appointment of Dr. Fujimoto as General Manager of our
Health Innovation Park is an important milestone that signals to
both our current and prospective partners, our continued commitment
to promote an open innovation ecosystem in Japan,” said Andrew
Plump, Chief Medical and Scientific Offer, Takeda. “I have every
expectation that Dr. Fujimoto’s passion, leadership skills and
R&D experience will be a tremendous asset in our efforts to
build a vibrant and exciting community for industry, government and
academia to incubate and accelerate the translation of cutting-edge
science into impactful healthcare solutions for patients in Japan –
and across the globe. I am excited to welcome him to our executive
team.”
Takeda has committed significant resources to the development of
its Health Innovation Park in Shonan as the Company seeks to
establish the first openly innovative ecosystem built on
pharmaceutical know-how in Japan.
Shonan Health Innovation Park Partners (as of 1st December)
- Axcelead Drug Discovery Partners, Inc.
- Cardurion Pharmaceuticals.
- Chordia Therapeutics, Inc.
- Noile-Immune Biotech, Inc.
- Oita UniversityInstitute of Advanced Medicine, Inc.
For more information about Takeda’s Innovation Ecosystem, visit
Ecosystem for health innovation.
For more information about Shonan Health Innovation Park, visit
shonan-health-innovation-park.com.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as Takeda’s presence in Emerging Markets,
are currently fueling the growth of Takeda. More than 30,000 Takeda
employees are committed to improving quality of life for patients,
working with Takeda’s partners in health care in more than 70
countries. For more information,
visit www.takeda.com/news.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward-looking statements include all statements other than
statements of historical fact, including plans, strategies and
expectations for the future, statements regarding the expected
timing of filings and approvals relating to the transaction, the
expected timing of the completion of the transaction, the ability
to complete the transaction or to satisfy the various closing
conditions, future revenues and profitability from or growth or any
assumptions underlying any of the foregoing. Statements made in the
future tense, and words such as “anticipate,” “expect,” “project,”
“continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,”
“potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,”
“assume,” “will,” “may,” “should,” and similar expressions are
intended to qualify as forward-looking statements. Forward-looking
statements are based on estimates and assumptions made by
management that are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Investors and
security holders are cautioned not to place undue reliance on these
forward-looking statements.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
that expressed or implied by the forward-looking statements. Some
of these risks and uncertainties include, but are not limited to:
required regulatory approvals for the transaction may not be
obtained in a timely manner, if at all; the conditions to closing
of the transaction may not be satisfied; competitive pressures and
developments; applicable laws and regulations; the success or
failure of product development programs; actions of regulatory
authorities and the timing thereof; changes in exchange rates; and
claims or concerns regarding the safety or efficacy of marketed
products or product candidates in development. The forward-looking
statements contained in this press release speak only as of the
date of this press release, and neither Portal Instruments nor
Takeda undertake any obligation to revise or update any
forward-looking statements to reflect new information, future
events or circumstances after the date of the forward-looking
statement. If one or more of these statements is updated or
corrected, investors and others should not conclude that additional
updates or corrections will be made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171130006314/en/
Takeda Pharmaceutical Company LimitedTatsuhiro Kanoo –
JapanTatsuhiro.kanoo@takeda.com+81 (0) 3-3278-3634orKelly Schlemm –
USAkelly.schlemm@takeda.com+1-617-551-8865